Lorence Kim, Moderna’s chief financial officer, exercised 241,000 options for $3 million on Monday, filings show. He then immediately sold them for $19.8 million, creating a profit of $16.8 million.

2026 and 2027 Financial Updates. Moderna is expanding its cost efficiency and prioritization programs and expects estimated GAAP operating costs of $5.4 to $5.7 billion in 2026, a reduction from ...

Moderna Chief Financial Officer Jamey Mock told Barron’s in mid-January that the company thinks it can still break even in 2028 and won’t need to raise new capital to get there.

Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label ...

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to ...

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the second ...

Moderna Inc. released new details about the abrupt departure of Chief Financial Officer Jorge Gomez, saying that it didn’t know of an internal investigation by his former employer Dentsply ...

Moderna’s Chief Financial Officer, Lorence Kim, M.D., will be leaving the Company in August after six years of service. The Company has retained Russell Reynolds to recruit for a new CFO with ...

David Meline joined Moderna as Chief Financial Officer on June 4. Mr. Meline previously served as Chief Financial Officer and EVP at Amgen (Nasdaq: AMGN) from 2014 through 2019.